Skip to content

ECIR SGLT2 Inhibitor Use - Owner Experience

Purpose of the Survey

This survey aims to gather information about owner experience with the use of SGLT2 inhibitors in equines with metabolic disorders (EMS/PPID). Your answers will be entered into a private database that may be used to improve understanding of the effects of SGLT2 inhibitors in EMS/PPID. You will not be identified and no personal information will be shared.

If you have copies of equine blood tests and forage analysis, having these nearby while you complete the survey will help.
1.Are you a member of the ECIR Outreach Group?
2.Do you have a case history with the ECIR Outreach Group?
3.If relevant, provide a link to your case history (paste in text box)
4.Equine Name
5.Equine age in years (no decimals or months, please)
6.Breed
7.Equine Weight (specify pounds or kilograms), estimate if unknown
8.Equine Body Condition
9.Equine Sex
10.Does your equine have EMS and/or PPID (Cushing's)? If NO, please exit survey)
11.If your equine has PPID, is ACTH controlled, i.e., blood tests confirm that ACTH is within acceptable seasonal limits?
12.Date SGLT2 inhibitor treatment started.
Please list date (MM/DD/YYYY)
13.Which SGLT2 inhibitor drug are you currently using? If you have used more than one, select them in the next question.
14.What was the starting dose? You may select mg/day or tablets/paste. If you started with one drug, then switched to another, select both. If unsure, give details in the comments box.
mg/kg
Tablets/Paste
Tablets per day (or dose of paste per day)
Canagliflozin (Invokana)
Ertugliflozin (Steglatro)
Dapagliflozin (Forxiga)
15.Were there changes to the dose over time?
16.If there were changes to the dose or drug, please list the drug name, date(s) and dose where changes were made. Skip if no change was made. Ex: 01/01/2024, switched to Invokana, 0.03 mg/kg OR 01/01/24, stopped Invokana, started Steglatro 0.025 mg/kg.
17.Before starting treatment with an SGLT2 inhibitor, did your equine have blood glucose over 100 mg/dL (5.5 mmol/L)?
18.Were blood triglycerides tested prior to starting the drug?
19.If triglycerides were tested before starting, what was the result? Please specify units of measure, either mmol/L or mg/dL
20.Were liver enzymes measured prior to starting the drug?
21.If liver enzymes were measured, what were the results? Since there are multiple liver enzymes, simply list normal, abnormal or don't know.
22.Was triglyceride testing repeated? If yes, please enter date (MM/DD/YYYY) and results with the unit of measure (mmol/L or mg/dL)
23.Was liver enzyme testing repeated? If yes, please list date (MM/DD/YYYY) below followed by result. Since there are multiple liver enzyme results, simply state "Normal" "Abnormal" or "I don't know."
24.Was the equine fasted for blood tests?
25.When you started using the drug, what was the daily hay ration? Please list by weight only (no flakes!) and specify either pounds or kilograms. If free choice feeding, select "Other."
Pounds
Kilograms
Hay
26.Do you have a forage analysis?
27.If you have a forage analysis, we would like to know the WSC, ESC, and starch in the AS FED or AS SAMPLED column. Some labs list only dry matter (one column). Note that some labs use the term "sugar" (ESC) or may not measure one of the above. Leave blank if unknown. Enter percent moisture at the bottom.
%WSC
%ESC
%Starch
As Fed or As Sampled Results
Dry Matter Results
28.Do you feed other feeds, for example, beet pulp, commercial feed (list brand), forage cubes or pellets? List product(s) followed by TOTAL DAILY amount in lbs or kg (no scoops!) Ex: Beet Pulp, 1 lb.
29.Do you use a vitamin mineral supplement?
30.Did your equine lose weight while on this drug without any intentional changes to the diet?
31.Did you find that you needed to make changes to the diet after starting the drug?
32.If you had to make changes to the diet, please explain why and what changes you had to make. Ex: added protein, amino acids, glycine, etc.
33.Were there any other side effects that you think might be related to treatment with SGLT2 inhibitor drugs?
34.Thank you for participating. Please list anything else you would like us to know about your experience using this type of drug, e.g., overall satisfaction, concerns, etc.
35.Are you willing to share your contact information should we have more questions?(Required.)
36.If willing, please enter your contact information.